AI-Based Predictions of Molecular Target Activity from Blind Chemical Structures
June 21, 2024
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
AI-Derived Therapeutic Development for the Treatment of Opioid Use Disorder
Read more
PNAS (Proceedings of the National Academy of Sciences): AI-derived therapeutic development of a serotonin receptor–targeting drug for the treatment of opioid use disorder
The opioid epidemic has led to a devastating loss of life nationwide. Of those dependent on opioids, many individuals desire to quit or red…
Read more